Nevro Stock Price, News & Analysis (NYSE:NVRO)

$77.40 -0.49 (-0.63 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$77.40
Today's Range$76.36 - $78.20
52-Week Range$65.00 - $99.63
Volume351,848 shs
Average Volume528,783 shs
Market Capitalization$2.29 billion
P/E Ratio-53.38
Dividend YieldN/A
Beta-0.83

About Nevro (NYSE:NVRO)

Nevro logoNevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:NVRO
CUSIPN/A
Phone+1-650-2510005

Debt

Debt-to-Equity Ratio0.59%
Current Ratio8.78%
Quick Ratio6.81%

Price-To-Earnings

Trailing P/E Ratio-53.3793103448276
Forward P/E Ratio-60.94
P/E GrowthN/A

Sales & Book Value

Annual Sales$228.50 million
Price / Sales10.04
Cash FlowN/A
Price / CashN/A
Book Value$8.66 per share
Price / Book8.94

Profitability

Trailing EPS($1.45)
Net Income$-31,770,000.00
Net Margins-7.57%
Return on Equity-10.30%
Return on Assets-5.82%

Miscellaneous

Employees518
Outstanding Shares29,630,000

Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) issued its quarterly earnings data on Monday, November, 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02. The medical equipment provider earned $82.26 million during the quarter, compared to the consensus estimate of $80.50 million. Nevro had a negative net margin of 7.57% and a negative return on equity of 10.30%. The company's revenue for the quarter was up 35.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.14) EPS. View Nevro's Earnings History.

When will Nevro make its next earnings announcement?

Nevro is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Nevro.

Where is Nevro's stock going? Where will Nevro's stock price be in 2018?

7 Wall Street analysts have issued 12-month price targets for Nevro's stock. Their predictions range from $85.00 to $110.00. On average, they expect Nevro's stock price to reach $99.71 in the next twelve months. View Analyst Ratings for Nevro.

What are Wall Street analysts saying about Nevro stock?

Here are some recent quotes from research analysts about Nevro stock:

  • 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (10/24/2017)
  • 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)

Who are some of Nevro's key competitors?

Who are Nevro's key executives?

Nevro's management team includes the folowing people:

  • Rami Elghandour, President, Chief Executive Officer (Age 38)
  • Andrew H. Galligan, Chief Financial Officer (Age 61)
  • Patrick Schmitz, Vice President - Operations (Age 57)
  • Michael Enxing, Vice President of Sales (Age 50)
  • Douglas A. Alleavitch, Vice President - Quality and Operations (Age 56)
  • Christopher Christoforou, Vice President - Research and Development (Age 47)
  • Ali Behbahani M.D., Independent Director (Age 40)
  • Lisa D. Earnhardt, Independent Director (Age 47)
  • Frank M. Fischer, Independent Director (Age 75)
  • Wilfred E. Jaeger M.D., Independent Director (Age 61)

Who owns Nevro stock?

Nevro's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (2.99%), Bank of Montreal Can (0.09%) and Hamilton Lane Advisors LLC (0.08%). Company insiders that own Nevro stock include Andre Walker, Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

Who bought Nevro stock? Who is buying Nevro stock?

Nevro's stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Hamilton Lane Advisors LLC and Bank of Montreal Can. View Insider Buying and Selling for Nevro.

How do I buy Nevro stock?

Shares of Nevro can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of Nevro stock can currently be purchased for approximately $77.40.

How big of a company is Nevro?

Nevro has a market capitalization of $2.29 billion and generates $228.50 million in revenue each year. The medical equipment provider earns $-31,770,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Nevro employs 518 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 Bridge Pkwy, REDWOOD CITY, CA 94065-1164, United States. The medical equipment provider can be reached via phone at +1-650-2510005 or via email at [email protected]


MarketBeat Community Rating for Nevro (NVRO)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nevro (NYSE:NVRO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.89
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $99.71$99.71$102.00$103.89
Price Target Upside: 46.21% upside46.21% upside10.63% upside40.50% upside

Nevro (NYSE:NVRO) Consensus Price Target History

Price Target History for Nevro (NYSE:NVRO)

Nevro (NYSE:NVRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017BMO Capital MarketsReiterated RatingBuy$100.00HighView Rating Details
11/7/2017Canaccord GenuityLower Price TargetBuy$120.00 -> $110.00N/AView Rating Details
11/7/2017Northland SecuritiesReiterated RatingBuy$96.00N/AView Rating Details
11/7/2017Leerink SwannReiterated RatingOutperform$105.00 -> $110.00N/AView Rating Details
8/8/2017Morgan StanleyBoost Price TargetOverweight$87.00 -> $95.00MediumView Rating Details
7/3/2017JPMorgan Chase & Co.Reiterated RatingOverweight$102.00LowView Rating Details
5/14/2017B. RileyDowngradeNeutral$85.00LowView Rating Details
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 -> $112.00N/AView Rating Details
8/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$90.00 -> $110.00N/AView Rating Details
8/8/2016Bank of AmericaInitiated CoverageBuy$100.00N/AView Rating Details
7/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
7/12/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Nevro (NYSE:NVRO) Earnings History and Estimates Chart

Earnings by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE NVRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($0.16)N/AView Earnings Details
11/6/2017Q3 2017($0.23)($0.21)$80.50 million$82.26 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.29)($0.40)$77.75 million$78.02 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.26)($0.50)$68.71 million$68.40 millionViewListenView Earnings Details
2/23/2017Q416($0.20)($0.34)$66.41 million$70.50 millionViewN/AView Earnings Details
11/7/2016Q316($0.39)($0.14)$58.05 million$60.92 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.31)$45.11 million$55.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.65)($0.33)$33.48 million$41.65 millionViewN/AView Earnings Details
2/29/2016Q415($0.56)($0.51)$32.88 million$33.10 millionViewListenView Earnings Details
11/9/2015Q315($0.75)($0.70)$12.51 million$15.40 millionViewN/AView Earnings Details
8/6/2015Q215($0.89)($0.77)$9.65 million$11.40 millionViewN/AView Earnings Details
5/11/2015Q1($0.54)($0.57)$8.20 million$9.66 millionViewListenView Earnings Details
3/18/2015Q4 2014($0.51)($0.59)$9.72 millionViewN/AView Earnings Details
12/2/2014Q3 2014($0.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Nevro (NYSE:NVRO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.73)
2019 EPS Consensus Estimate: ($0.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.34)($0.34)($0.34)
Q2 20181($0.23)($0.23)($0.23)
Q3 20181($0.16)($0.16)($0.16)
Q1 20192($0.33)$0.02($0.16)
Q2 20192($0.13)$0.09($0.02)
Q3 20191($0.06)($0.06)($0.06)
Q4 20191$0.04$0.04$0.04
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Nevro (NYSE:NVRO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Nevro (NYSE NVRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro (NYSE:NVRO)
Insider Trades by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE NVRO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Andrew H GalliganCFOSell7,000$75.11$525,770.00View SEC Filing  
10/5/2017Michael F DemaneDirectorSell5,000$93.50$467,500.00View SEC Filing  
9/27/2017Michael F. DemaneDirectorSell5,000$91.50$457,500.00View SEC Filing  
9/14/2017Wilfred E JaegerDirectorSell16,467$90.19$1,485,158.731,518View SEC Filing  
9/13/2017Michael F. DemaneDirectorSell5,000$89.50$447,500.00View SEC Filing  
9/11/2017Michael F. DemaneDirectorSell25,000$87.73$2,193,250.00View SEC Filing  
8/24/2017Wilfred E JaegerDirectorSell52,520$86.11$4,522,497.201,518View SEC Filing  
8/21/2017Wilfred E JaegerDirectorSell40,343$84.28$3,400,108.041,518View SEC Filing  
8/16/2017Wilfred E. JaegerDirectorSell79,657$82.74$6,590,820.18View SEC Filing  
8/15/2017Wilfred E. JaegerDirectorSell29,665$82.54$2,448,549.10View SEC Filing  
8/14/2017Andrew H. GalliganCFOSell7,000$82.31$576,170.00View SEC Filing  
8/14/2017Wilfred E. JaegerDirectorSell25,255$82.40$2,081,012.00View SEC Filing  
5/15/2017Andrew H. GalliganCFOSell7,500$75.30$564,750.00View SEC Filing  
5/2/2017Michael F DemaneDirectorSell29,800$96.07$2,862,886.00501,795View SEC Filing  
5/1/2017Rami ElghandourCEOSell10,000$95.03$950,300.00View SEC Filing  
4/4/2017Michael EnxingVPSell1,500$93.53$140,295.00View SEC Filing  
4/4/2017Michael F DemaneDirectorSell22,200$93.39$2,073,258.00517,795View SEC Filing  
4/3/2017Andrew H. GalliganCFOSell30,000$94.46$2,833,800.00View SEC Filing  
3/6/2017Michael EnxingVPSell38,500$91.01$3,503,885.00View SEC Filing  
3/3/2017Wilfred E JaegerDirectorSell43,980$95.03$4,179,419.40View SEC Filing  
1/4/2017Michael EnxingVPSell1,500$75.88$113,820.00View SEC Filing  
12/5/2016Michael EnxingVPSell1,500$76.38$114,570.00View SEC Filing  
11/15/2016Andrew H GalliganCFOSell7,500$86.90$651,750.0033,315View SEC Filing  
10/10/2016Rami ElghandourCEOSell3,000$100.00$300,000.00View SEC Filing  
10/6/2016Michael F DemaneDirectorSell139,514$97.46$13,597,034.44532,425View SEC Filing  
10/4/2016Michael EnxingVPSell1,500$99.31$148,965.0039,463View SEC Filing  
8/22/2016Doug AlleavitchVPSell3,000$100.00$300,000.005,961View SEC Filing  
8/22/2016Wilfred E JaegerDirectorSell154,840$97.79$15,141,803.60View SEC Filing  
8/17/2016Wilfred E JaegerDirectorSell155,160$97.31$15,098,619.60View SEC Filing  
8/15/2016Andrew H GalliganCFOSell7,500$97.71$732,825.0030,079View SEC Filing  
8/10/2016Doug AlleavitchVPSell2,500$95.00$237,500.006,961View SEC Filing  
8/9/2016Michael F DemaneDirectorSell26,667$91.50$2,440,030.50499,252View SEC Filing  
8/4/2016Michael EnxingVPSell1,500$82.06$123,090.0039,463View SEC Filing  
7/29/2016Doug AlleavitchVPSell1,000$85.00$85,000.007,961View SEC Filing  
7/29/2016Michael F DemaneDirectorSell13,333$84.00$1,119,972.00505,919View SEC Filing  
7/11/2016Doug AlleavitchVPSell2,000$80.00$160,000.008,961View SEC Filing  
7/11/2016Michael F DemaneDirectorSell13,333$79.00$1,053,307.00512,586View SEC Filing  
7/5/2016Michael EnxingVPSell1,500$75.39$113,085.0039,463View SEC Filing  
7/1/2016Michael F DemaneDirectorSell13,333$74.00$986,642.00519,253View SEC Filing  
6/8/2016Doug AlleavitchVPSell1,000$75.00$75,000.009,961View SEC Filing  
6/8/2016Rami ElghandourCEOSell7,000$76.59$536,130.0071,180View SEC Filing  
6/6/2016Michael EnxingVPSell1,500$73.29$109,935.0039,463View SEC Filing  
6/2/2016Andre WalkerVPSell4,000$73.50$294,000.004,197View SEC Filing  
6/1/2016Doug AlleavitchVPSell500$72.00$36,000.0010,961View SEC Filing  
5/18/2016Wilfred E JaegerDirectorSell112,983$64.68$7,307,740.44View SEC Filing  
5/16/2016Andrew H GalliganCFOSell10,000$64.78$647,800.0040,000View SEC Filing  
5/16/2016Michael F DemaneCEOSell39,999$64.77$2,590,735.23525,920View SEC Filing  
5/12/2016Rami ElghandourPresidentSell7,000$63.93$447,510.0068,024View SEC Filing  
5/4/2016Michael EnxingVPSell1,500$65.06$97,590.0038,913View SEC Filing  
4/4/2016Michael EnxingVPSell8,767$61.59$539,959.5346,180View SEC Filing  
4/1/2016Rami ElghandourPresidentSell7,000$60.99$426,930.0071,180View SEC Filing  
1/11/2016Andre WalkerVPSell7,987$70.75$565,080.25470View SEC Filing  
1/4/2016Doug AlleavitchVPSell2,514$66.47$167,105.5811,470View SEC Filing  
12/17/2015Andre WalkerVPSell13$69.00$897.00470View SEC Filing  
12/7/2015Rami ElghandourPresidentSell3,500$61.82$216,370.00View SEC Filing  
12/2/2015Andre WalkerVPSell1,000$64.00$64,000.00470View SEC Filing  
12/1/2015Andre WalkerVPSell8,000$59.50$476,000.00470View SEC Filing  
11/30/2015Andre WalkerVPSell6,000$58.50$351,000.00470View SEC Filing  
11/30/2015Rami ElghandourPresidentSell3,500$60.00$210,000.00View SEC Filing  
11/24/2015Andre WalkerVPSell1,000$55.00$55,000.00470View SEC Filing  
11/23/2015Andre WalkerVPSell1,000$54.00$54,000.00470View SEC Filing  
11/23/2015Wilfred E JaegerDirectorSell25,000$53.48$1,337,000.00View SEC Filing  
11/18/2015Wilfred E JaegerDirectorSell175,000$52.24$9,142,000.00View SEC Filing  
11/16/2015Michael F DemaneCEOSell26,667$50.52$1,347,216.84573,941View SEC Filing  
11/13/2015Brad ValeDirectorBuy2,000$50.76$101,520.002,000View SEC Filing  
9/17/2015Andre WalkerVPSell4,000$50.75$203,000.00View SEC Filing  
9/2/2015Michael F DemaneCEOSell40,001$45.11$1,804,445.11600,608View SEC Filing  
6/8/2015& Johnson JohnsonMajor ShareholderSell1,010,265$47.94$48,432,104.10View SEC Filing  
6/8/2015Bay City Capital LlcInsiderSell491,835$47.94$23,578,569.90View SEC Filing  
6/8/2015Wilfred E JaegerDirectorSell393,468$47.94$18,862,855.92View SEC Filing  
11/12/2014& Johnson JohnsonMajor ShareholderBuy40,000$18.00$720,000.00View SEC Filing  
11/12/2014A/S NovoInsiderBuy215,000$18.00$3,870,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nevro (NYSE NVRO) News Headlines

Source:
DateHeadline
Equities Analysts Set Expectations for Nevro Corps FY2017 Earnings (NVRO)Equities Analysts Set Expectations for Nevro Corp's FY2017 Earnings (NVRO)
www.americanbankingnews.com - January 18 at 6:44 AM
Nevro Corp Expected to Post Q3 2019 Earnings of ($0.06) Per Share (NVRO)Nevro Corp Expected to Post Q3 2019 Earnings of ($0.06) Per Share (NVRO)
www.americanbankingnews.com - January 17 at 11:14 PM
Analyzing Atrion (ATRI) & Nevro (NVRO)Analyzing Atrion (ATRI) & Nevro (NVRO)
www.americanbankingnews.com - January 17 at 1:28 AM
Nevro to Highlight Body of Clinical Evidence Supporting Expanded Use and Potential New Indications of Companys Senza Spinal Cord Stimulation Systems Delivering HF10™ Therapy at NANS Annual MeetingNevro to Highlight Body of Clinical Evidence Supporting Expanded Use and Potential New Indications of Company's Senza Spinal Cord Stimulation Systems Delivering HF10™ Therapy at NANS Annual Meeting
finance.yahoo.com - January 12 at 10:19 AM
Critical Review: Alliqua Biomedical (ALQA) vs. Nevro (NVRO)Critical Review: Alliqua Biomedical (ALQA) vs. Nevro (NVRO)
www.americanbankingnews.com - January 12 at 3:16 AM
Zacks: Brokerages Anticipate Nevro Corp (NVRO) Will Post Earnings of -$0.17 Per ShareZacks: Brokerages Anticipate Nevro Corp (NVRO) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - January 11 at 8:20 AM
Nevro (NVRO) Announces FDA Approval for Senza II Spinal Cord Stimulation System Delivering HF10 TherapyNevro (NVRO) Announces FDA Approval for Senza II Spinal Cord Stimulation System Delivering HF10 Therapy
www.streetinsider.com - January 8 at 4:43 PM
Nevro Corp. (NVRO) Is Up Sharply After FDA ApprovalNevro Corp. (NVRO) Is Up Sharply After FDA Approval
www.nasdaq.com - January 8 at 10:27 AM
Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2017 RevenueNevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2017 Revenue
finance.yahoo.com - January 8 at 10:27 AM
Nevro Receives FDA Approval for Senza II™ Spinal Cord Stimulation System Delivering HF10™ TherapyNevro Receives FDA Approval for Senza II™ Spinal Cord Stimulation System Delivering HF10™ Therapy
finance.yahoo.com - January 8 at 10:27 AM
Nevro Corp. :NVRO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Nevro Corp. :NVRO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 27 at 1:06 PM
ETFs with exposure to Nevro Corp. : December 27, 2017ETFs with exposure to Nevro Corp. : December 27, 2017
finance.yahoo.com - December 27 at 1:06 PM
 Analysts Expect Nevro Corp (NVRO) Will Announce Earnings of -$0.17 Per Share Analysts Expect Nevro Corp (NVRO) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - December 25 at 7:26 PM
Nevro Corp (NVRO) Given Consensus Recommendation of "Hold" by BrokeragesNevro Corp (NVRO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 25 at 5:40 AM
Nevro to Present at the 36th Annual J.P. Morgan Healthcare ConferenceNevro to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 4:36 PM
Free Research Report as Nevro’s Revenue Grew 35%Free Research Report as Nevro’s Revenue Grew 35%
finance.yahoo.com - December 18 at 10:42 AM
Nevros (NVRO) Buy Rating Reaffirmed at BMO Capital MarketsNevro's (NVRO) Buy Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - December 16 at 6:24 PM
$90.35 Million in Sales Expected for Nevro Corp. (NVRO) This Quarter$90.35 Million in Sales Expected for Nevro Corp. (NVRO) This Quarter
www.americanbankingnews.com - December 10 at 12:38 PM
Zacks: Brokerages Expect Nevro Corp. (NVRO) Will Post Earnings of -$0.17 Per ShareZacks: Brokerages Expect Nevro Corp. (NVRO) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - December 8 at 3:24 AM
Oversold Conditions For Nevro (NVRO) - NasdaqOversold Conditions For Nevro (NVRO) - Nasdaq
www.nasdaq.com - December 4 at 4:37 PM
Q1 2019 Earnings Estimate for Nevro Corp. Issued By Leerink Swann (NVRO)Q1 2019 Earnings Estimate for Nevro Corp. Issued By Leerink Swann (NVRO)
www.americanbankingnews.com - December 4 at 12:54 PM
Nevro získava CE označenie pre systém miechovej stimulácie Senza II™ zabezpečujúci liečbu HF10™Nevro získava CE označenie pre systém miechovej stimulácie Senza II™ zabezpečujúci liečbu HF10™
www.prnewswire.com - December 1 at 5:45 AM
Společnost Nevro získala označení CE pro systém míšní stimulace Senza II™ umožňující terapii HF10™Společnost Nevro získala označení CE pro systém míšní stimulace Senza II™ umožňující terapii HF10™
www.prnewswire.com - December 1 at 5:45 AM
Nevro Corp. (NVRO) Given Average Rating of "Hold" by BrokeragesNevro Corp. (NVRO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 5:56 AM
Nevro (NVRO) vs. MiMedx Group (MDXG) Head-To-Head SurveyNevro (NVRO) vs. MiMedx Group (MDXG) Head-To-Head Survey
www.americanbankingnews.com - November 26 at 3:40 PM
Nevro Corp. (NVRO) Lowered to "Strong Sell" at BidaskClubNevro Corp. (NVRO) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - November 26 at 6:10 AM
Nevro Corp. (NVRO) Expected to Announce Quarterly Sales of $90.45 MillionNevro Corp. (NVRO) Expected to Announce Quarterly Sales of $90.45 Million
www.americanbankingnews.com - November 22 at 9:08 AM
-$0.17 Earnings Per Share Expected for Nevro Corp. (NVRO) This Quarter-$0.17 Earnings Per Share Expected for Nevro Corp. (NVRO) This Quarter
www.americanbankingnews.com - November 20 at 7:40 AM
Insider Selling: Nevro Corp. (NVRO) CFO Sells 7,000 Shares of StockInsider Selling: Nevro Corp. (NVRO) CFO Sells 7,000 Shares of Stock
www.americanbankingnews.com - November 16 at 8:10 PM
Analyzing West Pharmaceutical Services (WST) and Nevro Corp. (NVRO)Analyzing West Pharmaceutical Services (WST) and Nevro Corp. (NVRO)
www.americanbankingnews.com - November 9 at 11:48 AM
Critical Contrast: Lombard Medical (EVAR) and Nevro Corp. (NVRO)Critical Contrast: Lombard Medical (EVAR) and Nevro Corp. (NVRO)
www.americanbankingnews.com - November 8 at 3:10 AM
Nevros (NVRO) CEO Rami Elghandour on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaNevro's (NVRO) CEO Rami Elghandour on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 2:46 AM
Nevro Corp. (NVRO) PT Lowered to $110.00Nevro Corp. (NVRO) PT Lowered to $110.00
www.americanbankingnews.com - November 7 at 9:06 PM
Nevro Corp. (NVRO) Earns "Outperform" Rating from Leerink SwannNevro Corp. (NVRO) Earns "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - November 7 at 12:08 PM
Nevro Corp. (NVRO) Earns "Buy" Rating from Northland SecuritiesNevro Corp. (NVRO) Earns "Buy" Rating from Northland Securities
www.americanbankingnews.com - November 7 at 11:33 AM
Nevro Corp. to Host Earnings CallNevro Corp. to Host Earnings Call
finance.yahoo.com - November 7 at 7:59 AM
Nevro Reports Third Quarter 2017 Financial ResultsNevro Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 7:59 AM
Edited Transcript of NVRO earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of NVRO earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 7:59 AM
Nevro Corp. (NVRO) Issues Quarterly  Earnings Results, Beats Estimates By $0.01 EPSNevro Corp. (NVRO) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 6 at 8:12 PM
Nevro Corp. (NVRO) Given Consensus Recommendation of "Hold" by AnalystsNevro Corp. (NVRO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 5 at 5:52 AM
Nevro Corp. (NVRO) Expected to Announce Quarterly Sales of $79.91 MillionNevro Corp. (NVRO) Expected to Announce Quarterly Sales of $79.91 Million
www.americanbankingnews.com - November 1 at 3:54 AM
Zacks: Analysts Expect Nevro Corp. (NVRO) to Announce -$0.23 Earnings Per ShareZacks: Analysts Expect Nevro Corp. (NVRO) to Announce -$0.23 Earnings Per Share
www.americanbankingnews.com - October 30 at 7:22 PM
Nevro Corp. (NVRO) to Release Earnings on MondayNevro Corp. (NVRO) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 10:43 AM
Nevro Corp. (NVRO) Downgraded by BidaskClub to "Sell"Nevro Corp. (NVRO) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - October 28 at 7:34 AM
Nevro Corp. breached its 50 day moving average in a Bearish Manner : NVRO-US : October 26, 2017Nevro Corp. breached its 50 day moving average in a Bearish Manner : NVRO-US : October 26, 2017
finance.yahoo.com - October 27 at 8:50 AM
ETFs with exposure to Nevro Corp. : October 24, 2017ETFs with exposure to Nevro Corp. : October 24, 2017
finance.yahoo.com - October 25 at 8:25 AM
Nevro Corp. (NVRO) vs. Its Peers Financial AnalysisNevro Corp. (NVRO) vs. Its Peers Financial Analysis
www.americanbankingnews.com - October 25 at 7:14 AM
Nevro to Report Operating Results for the Third Quarter 2017Nevro to Report Operating Results for the Third Quarter 2017
finance.yahoo.com - October 24 at 7:54 AM
Nevro Corp. (NVRO) & Its Competitors Critical SurveyNevro Corp. (NVRO) & Its Competitors Critical Survey
www.americanbankingnews.com - October 22 at 6:22 AM
Zacks Investment Research Lowers Nevro Corp. (NVRO) to SellZacks Investment Research Lowers Nevro Corp. (NVRO) to Sell
www.americanbankingnews.com - October 16 at 12:14 AM

SEC Filings

Nevro (NYSE:NVRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nevro (NYSE:NVRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nevro (NYSE NVRO) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.